La densidad es una propiedad fundamental en el ámbito de la física y la química. Entre los elementos que conforman la Tabla Periódica, algunos destacan por su asombrosa densidad, abriendo las puertas a un fascinante viaje a las profundidades del mundo subatómico. …
En los confines cósmicos donde la física se convierte en poesía, emergen las estrellas de quarks, fascinantes y esquivas, desafiando las nociones convencionales de la astronomía. Conozcamos estas luminarias exóticas, explorando su misteriosa naturaleza y su impacto …
Las alergias alimentarias se erigen como un enigma que afecta a millones en todo el mundo. Vamos a intentar arrojar luz sobre el origen de las alergias alimentarias, explorando los factores subyacentes y los avances científicos que nos acercan a comprender este fenómeno de reacciones i …
InnoCare Pharma announced that phase II clinical study results of novel TYK2 inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis.
Astellas Pharma Inc. contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium.
GC Biopharma Corp announces that the US Food and Drug Administration has approved ALYGLO 10% Liquid, formerly referred to as “GC5107,” for the treatment of adult patients aged 17 years and older with primary humoral immunodeficiency.
InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer.
InnoCare Appoints Xin Fu as Chief Financial Officer Read More »
Innovent Biologics, Inc. announces that results of a Phase 2 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese patients with overweight or obesity were published in Nature Communications.
The agency is investigating reports of secondary blood cancers in patients who have received certain CAR T cell therapies, but experts say the risk is low and is outweighed by the terminal nature of some cancers.
The year may be coming to a close, but there’s no holiday break for the FDA, which will release five regulatory verdicts over the next two weeks.
FDA Action Alert: Calliditas, Ionis/AstraZeneca, Amgen and More Read More »
